文献速递技术与安全儿科影像MR

磁共振静脉对比剂使用的安全性问题

Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
PubMed 文献 · Pediatr Radiol · 2021-04-19

本文综述了钆基对比剂(GBCA)在成人和儿童MRI中的安全性,重点关注急性不良反应、肾源性系统性纤维化和钆沉积,并讨论了非钆对比剂ferumoxytol的风险特征及高危特殊人群。

要点

  • 钆基对比剂总体安全记录良好,但存在急性不良反应、肾源性系统性纤维化和钆沉积等风险。
  • 非钆对比剂ferumoxytol使用增加,具有自身风险特征,需关注。
  • 识别高危特殊人群有助于降低GBCA相关伤害风险。

局限性

  • 为综述性文章,未提供原始研究数据或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Ponrartana S, Moore MM, Chan SS, et al. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol. 2021. PMID: 33871726. doi:10.1007/s00247-020-04896-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。